Authors
Latest:
Looking Ahead in the Multiple Myeloma Treatment LandscapeExperts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.
Latest:
Relapsed/Refractory Multiple Myeloma: Practice Pearls and Future Directions in CareThomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, share closing thoughts on the evolving landscape of cytokine release syndrome management in relapsed/refractory multiple myeloma.
Latest:
Radiation Therapy in Diffuse Large B-Cell Lymphoma: A Little Boost Gets You Over the Finish LineBradford S. Hoppe, MD, MPH, and Omran Saifi, MD, offer a peer perspective on research by Gavin Jones, MD, and colleagues into radiation therapy in diffuse large B-cell lymphoma.
Latest:
Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature ReviewInvestigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Latest:
Between the Lines™ Podcast: ctDNA as a Biomarker of Progression in Colorectal CancerLiliana Bustamante, MD, and Richard Kim, MD, discuss circulating tumor DNA as a potential prognostic biomarker for patients with colorectal cancer.
Latest:
Disorders of Sex Development and Malignant Germ Cell TumorsKey points: Patients with disorders of sex development (DSDs) are at an increased risk of malignant germ cell tumors (GCTs). In adulthood, the partial form of androgen insensitivity syndrome confers the greatest risk of developing malignant GCTs. Gonadoblastoma is the most common gonadal GCT arising in patients with DSDs. Despite being a benign neoplasm, it can undergo malignant transformation in up to 60% of patients with a DSD. Oncologic treatment in patients with disorders of sex development and malignant GCTs does not differ from the standard treatment for testicular GCTs. Treatment of patients with DSDs requires a multidisciplinary team, including a psychiatric, genetic, and reproductive assessment as well as the involvement of an ethics committee. An early diagnosis of DSDs is crucial to avoid the development of potentially serious complications in adulthood.
Latest:
Oncology Peer Review On-The-Go: Value of Geriatric Assessment in Patients With Genitourinary CarcinomasLead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.
Latest:
Future Perspectives and Unmet Needs in Multiple MyelomaThe expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Latest:
Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.
Latest:
Oncology Peer Review On-The-Go: Cancer Pain and Opioid Use DisorderAuthors Daniel C. McFarland, DO, and Kirk Harris, MD, spoke with CancerNetwork® about their manuscript on cancer pain’s relationship with opioid use disorder that was recently published in the journal ONCOLOGY®.
Latest:
Addressing Resistance to Targeted Therapies in Metastatic Colorectal CancerInvestigators discuss the use of targeted therapies to treat metastatic colorectal cancer.
Latest:
Efficacy and Safety of Zolbetuximab in Gastric CancerZolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
Latest:
Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ MelanomaPhase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.
Latest:
A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity ReactionStacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.
Latest:
Value of Geriatric Assessment in Patients With Genitourinary CarcinomaThis work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.
Latest:
Future Perspectives on MRD Testing in Colorectal CancerThe expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.
Latest:
A Multidisciplinary Approach to Treating Resectable NSCLCSurgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.
